In the human lung adenocarcinoma epithelial Calu-3 cell line, it was shown that treatment with the ErbB2-targeting antibody trastuzumab was associated with increased cellular ROS production, glutathione depletion, and decreased superoxide dismutase and catalase activities (77). The gene discussed is ERBB2; the disease is lung adenocarcinoma.